This NIH/NCI funding opportunity supports innovative research to discover novel small molecules that advance cancer biology and therapy. Projects may include assay development, primary screening, and hit validation to identify chemical probes, drug candidates, or immunomodulators. The program is designed to stimulate early-stage discovery and provide critical tools for cancer research and drug development.
Eligibility criteria:
-
Open to higher education institutions (public and private).
-
Nonprofits with or without 501(c)(3) status.
-
For-profit organizations including small businesses.
-
State, local, and tribal governments.
-
Foreign organizations and foreign components are eligible.
-
PD/PI must have an eRA Commons account and all standard NIH registrations.
Funding details:
-
Budget not limited, must reflect actual project needs.
-
Project period up to 3 years.
-
Requests of 500,000 USD or more in direct costs per year require pre-approval from NCI.
Deadline:
-
Standard NIH dates: February 5, June 5, October 5 (2025–2026).
-
Expiration date: September 8, 2026.
Where to go for further information:
-
General grants information: [email protected]